Virtual Meetings 2023

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders

For an up-to-date schedule of upcoming sessions in this series, please click here.


Richard F Riedel, MD
Associate Professor of Medicine with Tenure
Associate Director, Clinical and Translational Research
Duke Sarcoma Center
Duke Cancer Institute
Duke University
Durham, North Carolina

Brian Van Tine, MD, PhD
Professor of Medicine and of Pediatrics
Director, Developmental Therapeutics (Phase 1) Program
Sarcoma Program Director
Barnes-Jewish Hospital
Washington University
St Louis, Missouri

Neil Love, MD
Research To Practice

These activities are supported by educational grants from Genentech, a member of the Roche Group, and SpringWorks Therapeutics Inc.


Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for soft tissue sarcoma and other related connective tissue disorders. Each event will employ an identical format that will include the following elements:

  • Moderator Dr Neil Love and a featured participating clinical investigator
  • Discussion of participating faculty treatment recommendations
  • Review of available clinical research findings
  • Community oncologist video case presentations
  • Interactive audience polling and extensive Q&A

    MODULE 1: Systemic Treatment for Metastatic Soft Tissue Sarcoma (STS)

    MODULE 2: Novel Approaches to the Management of Unique STS Subtypes

    MODULE 3: Selection and Sequencing of Systemic Therapy for Patients with Advanced Gastrointestinal Stromal Tumors

    MODULE 4: Current and Future Treatment for Noncancerous Neoplasms Affecting Soft Tissue

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of soft tissue sarcoma and other related connective tissue disorders.

Learning Objectives

  • Recognize the histologic diversity of soft tissue sarcomas (STS), and appreciate the importance of appropriate assessment and accurate diagnosis in facilitating optimal treatment and long-term outcomes for patients.
  • Consider the influence of age, histology, extent of disease and other clinical and biological factors in the selection and sequencing of therapy for patients with STS.
  • Explore the clinical trial database supporting the use of agents with established activity in various subtypes of STS, such as multitargeted tyrosine kinase inhibitors, TRK inhibitors, mTOR inhibitors and EZH2 inhibitors, and use this information to identify patients for whom treatment with these strategies may be appropriate.
  • Assess the biological rationale for the evaluation of immune checkpoint inhibition for STS, and consider the current and potential roles of anti-PD-1/PD-L1 antibody therapy in the management of various subtypes of the disease.
  • Recall new data with investigational agents and strategies demonstrating promising activity for STS, and appropriately refer eligible patients for trial participation.
  • Understand the incidence, risk factors, etiology and clinical presentation of desmoid tumors in order to optimally diagnose patients with this disease.
  • Evaluate the scientific rationale for targeting the gamma secretase complex and Notch pathway as a therapeutic approach for desmoid tumors, and review available research findings establishing the efficacy and potential clinical role of this novel treatment strategy.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Van TineBoard Member: Polaris Pharmaceuticals; Consulting Agreements: Acuta Capital Partners LLC, Advenchen Laboratories LLC, Bayer HealthCare Pharmaceuticals, Boxer Capital LLC, Cytokinetics, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, EcoR1 Capital LLC, Putnam Associates, Salarius Pharmaceuticals Inc; Contracted Research: GSK, Merck, Pfizer Inc, TRACON Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Aadi Bioscience, Agenus Inc, Apexigen, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Curis Inc, Daiichi Sankyo Inc, EcoR1 Capital LLC, PTC Therapeutics, Regeneron Pharmaceuticals Inc; Patents/Licensing: Accuronix Therapeutics; Speakers Bureau: Iterion Therapeutics; Nonrelevant Financial Relationship: Targeted Oncology, Total Health Conferencing.

SERIES MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

These activities are supported by educational grants from Genentech, a member of the Roche Group, and SpringWorks Therapeutics Inc.